Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

103.00 -8.40 (-7.54%)
Streaming Delayed Price Updated: 12:43 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
News headline image
5 Stocks To Ride The German Market Rally ↗
 
Via Benzinga
News headline image
Accenture To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
12 Analysts Have This To Say About BioNTech ↗
 
Via Benzinga
News headline image
Market Monitor News June 13 (Oracle UP - Gamestop DOWN) ↗
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation. 
Via Chartmill
Topics Artificial Intelligence Economy
News headline image
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal ↗
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
News headline image
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment ↗
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares. 
Via Stocktwits
News headline image
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading ↗
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
Via Benzinga
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
News headline image
Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines? ↗
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust." 
Via Stocktwits
Topics Government
News headline image
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
News headline image
Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Market Monitor News June 03 (Cleveland-Cliffs, Blueprint Medicines UP - First Solar DOWN) ↗
Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses 
Via Chartmill
News headline image
Why BioNTech Stock Soared Today ↗
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
News headline image
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug ↗
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion. 
Via Benzinga
News headline image
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug ↗
BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
Via Stocktwits
Topics Government
News headline image
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
News headline image
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From BioNTech SE
Via GlobeNewswire
News headline image
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
News headline image
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
News headline image
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. ↗
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
News headline image
What's Going On With Vaccine Stocks Today? ↗
Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week. 
Via Benzinga
News headline image
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. ↗
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
News headline image
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
News headline image
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny ↗
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
Via Benzinga
News headline image
Where BioNTech Stands With Analysts ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.